COSCIENS Biopharma Inc.
CSCIF Healthcare Biotechnology
COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS grew 92.6% and free cash flow grew 113.3%, each against the same quarter a year earlier.
Follow CSCIF
COSCIENS Biopharma Inc. (CSCIF) P/E ratio
As of 16 October 2026, COSCIENS Biopharma Inc. (CSCIF) trades at a P/E ratio of 1.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 14.6× (May 2018); the current reading is higher than 92% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 3.8× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.4× | 40.27% |
| Mar 2026 | 0.3× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| IMRN IMMURON compare | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | 0.0× |
| CSCIF COSCIENS Biopharma Inc. | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)